NasdaqCM:IMAC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

IMAC Holdings, Inc. provides orthopedic therapies through a chain of innovative medical advancements and care regeneration centers in the United States. More Details


Snowflake Analysis

Overvalued with concerning outlook.

Share Price & News

How has IMAC Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IMAC's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

4.9%

IMAC

1.3%

US Healthcare

1.3%

US Market


1 Year Return

-75.1%

IMAC

21.2%

US Healthcare

15.8%

US Market

Return vs Industry: IMAC underperformed the US Healthcare industry which returned 21.2% over the past year.

Return vs Market: IMAC underperformed the US Market which returned 15.8% over the past year.


Shareholder returns

IMACIndustryMarket
7 Day4.9%1.3%1.3%
30 Day-21.9%-4.3%-4.1%
90 Day-34.6%-0.7%8.4%
1 Year-75.1%-75.1%22.8%21.2%18.4%15.8%
3 Yearn/a23.8%18.5%38.2%29.0%
5 Yearn/a50.2%39.6%84.9%64.0%

Price Volatility Vs. Market

How volatile is IMAC Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is IMAC Holdings undervalued compared to its fair value and its price relative to the market?

0.92x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IMAC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IMAC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IMAC is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.

PE vs Market: IMAC is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IMAC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IMAC is good value based on its PB Ratio (0.9x) compared to the US Healthcare industry average (2.8x).


Next Steps

Future Growth

How is IMAC Holdings forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-2.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IMAC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IMAC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IMAC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IMAC's revenue (16.7% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: IMAC's revenue (16.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if IMAC's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has IMAC Holdings performed over the past 5 years?

-68.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IMAC is currently unprofitable.

Growing Profit Margin: IMAC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IMAC is unprofitable, and losses have increased over the past 5 years at a rate of 68% per year.

Accelerating Growth: Unable to compare IMAC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IMAC is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (31.1%).


Return on Equity

High ROE: IMAC has a negative Return on Equity (-85.44%), as it is currently unprofitable.


Next Steps

Financial Health

How is IMAC Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: IMAC's short term assets ($4.9M) do not cover its short term liabilities ($8.8M).

Long Term Liabilities: IMAC's short term assets ($4.9M) do not cover its long term liabilities ($5.2M).


Debt to Equity History and Analysis

Debt Level: IMAC's debt to equity ratio (73%) is considered high.

Reducing Debt: Insufficient data to determine if IMAC's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IMAC has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: IMAC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 41% each year


Next Steps

Dividend

What is IMAC Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IMAC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IMAC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IMAC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IMAC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IMAC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average board tenure


CEO

Jeff Ervin (43 yo)

no data

Tenure

US$1,451,877

Compensation

Mr. Jeffrey S. Ervin, also known as Jeff, has been the Chairman and Director of IMAC Holdings, Inc. since 2018 and serves as its Chief Executive Officer. Mr. Ervin Co-Founded IMAC Holdings in March 2015. M ...


CEO Compensation Analysis

Compensation vs Market: Jeff's total compensation ($USD1.45M) is above average for companies of similar size in the US market ($USD601.03K).

Compensation vs Earnings: Jeff's compensation has increased whilst the company is unprofitable.


Board Members

NamePositionTenureCompensationOwnership
Jeffrey Ervin
Chairman & CEOno dataUS$1.45m2.5%
$ 220.8k
Matthew Wallis
COO & Director2.67yrsUS$257.27k18.17%
$ 1.6m
Gerard Hayden
Independent Director0.58yrno data0.084%
$ 7.5k
David Ellwanger
Independent Director1.5yrsUS$134.10k0.17%
$ 14.9k
George Hampton
Independent Director1.5yrsUS$134.10k0.19%
$ 16.5k

1.5yrs

Average Tenure

50yo

Average Age

Experienced Board: IMAC's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: IMAC insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 40.8%.


Top Shareholders

Company Information

IMAC Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: IMAC Holdings, Inc.
  • Ticker: IMAC
  • Exchange: NasdaqCM
  • Founded: 2000
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Market Cap: US$8.821m
  • Shares outstanding: 11.84m
  • Website: https://www.imacregeneration.com

Number of Employees


Location

  • IMAC Holdings, Inc.
  • 1605 Westgate Circle
  • Brentwood
  • Tennessee
  • 37027
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IMACNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDFeb 2019
I02DB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2019

Biography

IMAC Holdings, Inc. provides orthopedic therapies through a chain of innovative medical advancements and care regeneration centers in the United States. Its outpatient medical clinics provide regenerative, ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/29 00:07
End of Day Share Price2020/09/28 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.